ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis - ACR Meeting Abstracts
Por um escritor misterioso
Descrição
Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF inhibitor therapy. However, despite a low disease activity measured by BASDAI, some patients complain of pain or are found in high inflammatory status. In such cases, other disease activity measurement […]
PDF) Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis
Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors - ACR Meeting Abstracts
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial - ACR Meeting Abstracts
PDF) The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases
Raising the Bar for Optimal Management of Axial Spondyloarthritis - European Medical Journal
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Treat-to-target in axial spondyloarthritis — what about physical function and activity?
Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study
Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis
Axial involvement in psoriatic arthritis: An update for rheumatologists - ScienceDirect
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial - ACR Meeting Abstracts
PDF) ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
